GleamWall
中文EN

AVXL ANAVEX LIFE SCIENCES CORP.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1314052 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY73.0%
TTM EPS YoY75.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-12.8%
ROA-11.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets6.4%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.25x
Accruals ratio14.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-09-30FY20242024-09-30
Income statement
Revenue——
R&D expense$37.59M$41.84M
SG&A expense$13.82M$11.04M
Operating income-$51.41M-$52.88M
Pretax income-$46.38M-$43.00M
Net income-$46.38M-$43.00M
EPS (basic)-0.54-0.52
EPS (diluted)-0.54-0.52
Weighted avg. shares (diluted)85.29M83.47M
Banking
Net interest income$4.68M$7.32M
Balance sheet
Cash & equivalents$102.58M$132.19M
Total assets$103.81M$135.57M
Total liabilities$8.95M$15.30M
Shareholders' equity$94.87M$120.26M
Shares outstanding86.67M84.80M
Cash flow statement
Operating cash flow-$39.04M-$30.81M
Financing cash flow$9.43M$11.97M
Stock-based compensation$11.55M$9.44M

Free plan shows the latest 2 periods; Pro shows all 21 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.